Introduction {#S0001}
============

The burden of the people living with human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS) is largely borne by communities in Sub-Saharan Africa[@CIT0001] in which Nigeria is included.

Kidney disease is an important complication in HIV patients with an increasing rate in its prevalence. This kidney-related disease tends to occur more often in patients with advanced stage of the HIV infection with lower CD~4~ counts and is associated with a high rate of morbidity and mortality.[@CIT0002]

Relevant comorbid conditions such as chronic kidney disease (CKD) and end-stage renal disease (ESRD) are found in HIV-infected individuals.[@CIT0003] Also, the risk of ESRD as shown by the United States renal data system is said to be 50-fold higher in African Americans living with HIV than in HIV-infected white patients.[@CIT0004]

About 30% of HIV-infected patients have been shown to have abnormal kidney function, with HIV-related kidney disease becoming a main cause of ESRD requiring dialytic intervention, with subsequent progression of kidney disease to AIDS and ultimately death.[@CIT0005]

In Nigeria, the overall prevalence of renal disorders among HIV-infected patients is not known. A study from Ile--Ife reported a prevalence of 38% for HIV-associated nephropathy (HIVAN),[@CIT0006] while another study in Jos showed a prevalence of 51.8% for renal disease in HIV-infected patients[@CIT0007] Other studies done in South-East and South-West Nigeria showed prevalences of 22.9%[@CIT0008] and 23.5%[@CIT0009] respectively.

A study in Baltimore, USA showed that, in a kidney biopsy report amongst some CKD patients of African American descent, there was a 3-fold higher rate in the risk of progression to ESRD with HIVAN than in those with other forms of renal histopathologic lesions.[@CIT0010]

The pathologic characteristics of HIV-associated CKD is varied in nature, with biopsy and autopsy series showing a wide range of pathologic lesions during analysis of the tissues.[@CIT0011]--[@CIT0014] However, among the African descendants, mostly found is the collapsing variant of focal segmental glomerulosclerosis, termed "HIVAN,"[@CIT0011],[@CIT0014],[@CIT0015] which has been reported to have a more aggressive downward course and rapid progression to ESRD.[@CIT0016],[@CIT0017]

The increased availability and usage of HAART by HIV-infected patients has influenced the rise of kidney diseases, as most HIV patients now live longer to develop such complications associated with the kidneys.[@CIT0018] However, there is an appreciable reduction in the risk of developing ESRD by 40--60%, mainly due to the slower clinical course of kidney disease among HIV patients, with an attendant increase from 25% to 75% in the 1-year survival rate while undergoing dialysis and renal transplantation is a successful treatment option.[@CIT0019],[@CIT0020]

Kidney disease and its associated risk factors are frequently found among HIV-infected patients, irrespective of the improvements with the use of HAART, and it remains a cause of morbidity and mortality.[@CIT0021] The associated risk factors for kidney in this population include black race, older age, hypertension, diabetes, low CD~4~ cell count, and high viral load.[@CIT0021]

Also, acute or chronic kidney disease has been shown to be associated with the use of antiretroviral regimens.[@CIT0021] Drugs such as tenofovir and some protease inhibitors have been implicated as a cause of severe renal impairment.[@CIT0022]

There are still very few studies in Nigeria, particularly in the South-South region of the country where our institution is located that conducted a study on the prevalence and predictors of CKD among HIV patients on HAART.

These findings prompted us to undertake this study in order to determine the prevalence and risk factors associated with CKD in HIV patients on HAART at the University of Calabar Teaching Hospital, Calabar.

Materials and methods {#S0002}
=====================

Study design, settings, and population {#S0002-S2001}
--------------------------------------

This was a cross-sectional study that was conducted in the special treatment clinic for HIV patients at the University of Calabar Teaching Hospital (UCTH), Calabar over a 4 month period from May to August, 2018.

A total of 118 HIV patients on HAART attending the special treatment clinic were consecutively recruited after meeting the study criteria and all participants provided written informed consent.This study was conducted in accordance with the Declaration of Helsinki.

All subjects underwent interview by using a structured questionnaire.

Information regarding patients' age, sex, occupation, religion, and educational status were obtained. Moreso, information on the family history of hypertension and history suggestive of renal disease were obtained. All subjects were fully examined and anthropometric measurements such as weight and height were taken by the investigators. Body mass index (BMI) was calculated from these. Subjects in the study had their blood pressures measured using a mercury sphygmomanometer and a standard sized cuff using the usual methods with the patient sitting quietly. The mean of two readings taken at least 2 minutes apart after the patient had rested in a relaxed sitting position for 5 minutes in a quiet room was recorded as the blood pressure.

Hypertension was defined as systolic blood pressure (SBP) 140 mmHg at least and/or diastolic blood pressure (DBP) 90 mmHg at least, using the Joint National Committee 7 (JNC 7) guideline or history of hypertension with the use of antihypertensive medications.

Samples for urine and blood were obtained from the participants at first contact with the investigators during the clinic visits of the HIV patients.

Urinalysis with multistix (combi -- 9) were carried out on all participants for the presence of overt proteinuria. Serum creatinine value was measured using alkaline picrate method while the creatinine clearance was calculated using the cockcroft and Gault formula for predicting glomerular filtration rate (GFR) as follows: $$\documentclass[12pt]{minimal}
\usepackage{wasysym}
\usepackage[substack]{amsmath}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage[mathscr]{eucal}
\usepackage{mathrsfs}
\DeclareFontFamily{T1}{linotext}{}
\DeclareFontShape{T1}{linotext}{m}{n} {linotext }{}
\DeclareSymbolFont{linotext}{T1}{linotext}{m}{n}
\DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext}
\begin{document}
$${{\left({{\rm{140 - Age\,in\,year}}} \right)\, \times {\rm{weight}}\,\left({{\rm{kg}}} \right)\, \times \,{\rm{0}}{\rm{.85\,for\,women}}} \over {72\, \times \,{\rm{serum\,creatinine\,}}\left({{\rm{mg/dl}}} \right).}}$$
\end{document}$$

This formula is readily preferred due to its simplicity and good predictive ability of GFR in HIV -- positive patients.[@CIT0023]

The subjects were classified using the GFR according to the National Kidney Foundation using the Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines as follows[@CIT0024]

Stage 1 (Normal or increased eGFR) ≥90 mL/min/1.73 m^2^

Stage 2 (Mildly decreased eGFR) =60--89 mL/min/1.73 m^2^

Stage 3 (Moderately decreased eGFR) =30--59 mL/min/1.73 m^2^

Stage 4 (Severely decreased eGFR) =15--29 mL/min/1.73 m^2^

Stage 5 (Kidney failure) \<15 mL/min/1.73 m^2^

Chronic kidney disease was therefore defined based on either of the two criteria. First, on the eGFR of \<60 mL/min[@CIT0024] and secondly on elevated plasma creatinine levels using values for the classification of chronic progressive renal disease[@CIT0025]

Reduced renal reserve (88.4--221 mmol/L)

Renal insufficiency (221--530.4 mmol/L)

Renal failure (486.2--972.4 mmol/L)

ESRD (\>707.2 mmol/L)

Inclusion criteria {#S0002-S2002}
------------------

Patients confirmed to have been diagnosed with HIV and on HAART at UCTH.HIV patients aged 18 years and above.HIV patients that consent to the study.

Exclusion criteria {#S0002-S2003}
------------------

HIV patients with comorbid conditions such as diabetes and liver cirrhosis.HIV patients below 18 years of age.HIV patients that do not give consent.

Data analysis {#S0002-S2004}
-------------

The data obtained were inputted and analyzed using Statistical Package for Social Sciences (SPSS) version 18. Continuous variables and categorical variables were expressed as means ± SD and percentages respectively. Comparison of means was done using Independent sample Student *t*-test and ANOVA; and Bivariate Correlation and Binary Logistic regression were used to determine the predictors of CKD. Other statistical tests were used as appropriate. *p*\<0.05 was accepted to be significant.

Ethical consideration {#S0003}
=====================

Ethical approval was duly applied for and subsequently obtained from the Health Research Ethical Committee (HREC) of the University of Calabar Teaching Hospital, Calabar.

Results {#S0004}
=======

[Table 1](#T0001){ref-type="table"} shows more female participants (69.5%) with about 58.3% of the patients below the age of 41 years and 15.3% of the participants having eGFR below 60 mls/min. The majority of the participants were married (54.2%), had secondary education (40.7%), were mainly business persons (62.7%) and resided in the urban region (73.7%). About half of the participants were on tenofovir-based combination ARV. Table 1Clinical and demographic characteristics of participantsVariablesFrequency (%), N=118**Gender**Female82 (69.5%)Male36 (30.5%)**Age category (years)**18--3020 (16.9%)31--4050 (42.4%)41--5031 (26.3%)51--6012 (10.2%)Above 605 (5.2%)**eGFR category (mls/min)**≥9046 (39.0%)60--8934 (45.7%)30--5916 (13.6%)15--292 (1.7%)˂150 (0.0%)**Marital status**Single37 (31.4%)Married64 (54.2%)Divorced4 (3.4%)Widow13 (11.0%)**Educational level**No formal education2 (1.7%)Primary21 (17.8%)Secondary48 (40.7%)Tertiary47 (39.8%)**Occupation**Student4 (3.4%)Civil servant26 (22.0%)Public servant14 (11.9%)Business (artisans, traders)74 (62.7)**Place of residence**Urban87 (73.7%)Rural31 (26.3%)**Ethnic group**Efik37 (31.4%)Ejagham19 (16.1%)Ibibio47 (38.8%)Anang9 (7.6%)Others (Igbo, Hausa, Yoruba)6 (5.1%)**ARV therapy**ABC/AZT/EFV1 (0.8%)3TC/AZT/NVP42 (35.6%)TDF/AZT/EFV8 (6.8%)ABC/3TC/EFV15 (12.7%)TDF/3TC/EFV37 (31.4%)TDF/3TC/LPVr15 (12.7%)[^1]

[Table 2](#T0002){ref-type="table"} showed that participants with a CD~4~ count ≤200 and those on TDF/3TC/EFV ARV therapy are more likely to develop CKD with significant values of 0.006 and 0.038 respectively. Table 2Cross tabulation of clinical and biochemical parametersVariablesCKD present (eGFR \<60 mL/min), N=18, (%)CKD absent (eGFR \>60 mL/min), N=100, (%)*p*-value**Age category (years)**18--302 (11.1)18 (18.0)0.481\*31--406 (33.3)44 (44.0)41--505 (27.8)26 (26.0)51--603 (16.7)9 (9.0)\>602 (11.1)3 (3.0)**Gender**Female11 (61.1)71 (71.0)0.402Male7 (38.9)29 (29.0)**HIV duration (months)**≤60 months12 (66.7)48 (48.0)0.145\>60 months6 (33.3)52 (52.0)**CD~4~count (cells/µL)**≤2008 (44.4)16 (16.0)0.006\>20010 (55.6)84 (84.0)**ARV therapy**ABC/AZT/EFV0 (0.0)1 (1.0)0.038\*3TC/AZT/NVP2 (11.1)40 (40.0)TDF/AZT/EFV3 (16.7)5 (5.0)ABC/3TC/EFV5 27.8)10 (10.0)TDF/3TC/EFV7 (38.9)30 (30.0)TDF/3TC/LPVr1 (5.6)14 (14.0)**Hypertension**Yes6 (33.3)25 (25.0)0.46No12 (66.7)75 (75.0)[^2]

In [Table 3](#T0003){ref-type="table"}, the mean WHR and creatinine levels are significantly higher in subjects with CKD (*p*\<0.05) while the mean weight, BMI, eGFR and CD~4~ count levels are significantly lower in subjects with CKD (*p*\<0.05). Table 3Relationship between CKD and some selected variablesVariablesCKD present (eGFR \<60 mL/min), N=18CKD absent (eGFR \>60 mL/min), N=100*p*-value**Age (years)**44.17±11.8739.22±9.650.109**HIV duration (months)**50.78±48.4470.71±45.580.119**SBP**114.44±21.48113.10±19.050.806**DBP**70.56±16.6270.00±13.480.895**Weight (kg)**59.89±12.2968.72±13.060.010**BMI (kg/m^2^)**23.47±4.7626.01±4.370.046**WHR**0.93±0.030.91±0.050.020**PCV (%)**29.10±5.3731.73±5.690.070**Creatinine (µmoL/L)**133.13±46.0685.73±19.130.001**eGFR (mL/min)**50.59±11.2890.67±20.780.001**CD~4~ count (cells/µL)**293.11±235.42446.73±242.060.018**ARV duration (months)**46.72±47.8865.35±43.730.138[^3]

[Table 4](#T0004){ref-type="table"} shows that the weight, BMI, PCV and CD~4~ count levels are directly correlated with eGFR, while creatinine levels are inversely correlated. Table 4Correlation of eGFR and some selected variablesVariablesCorrelation coefficient*p*-value**Age years)**−0.1770.056**HIV duration (months)**0.1370.140**SBP**−0.0180.843**DBP**0.0190.835**Weight (kg)**0.36\*\*0.0001**BMI (kg/m^2^)**0.327\*\*0.0001**WHR**−0.1080.246**PCV (%)**0.319\*\*0.0001**Creatinine (µmol/L)**−0.678\*\*0.0001**CD~4~ count (cells/µL)**0.216\*0.019**ARV duration (months)**0.1480.110[^4][^5]

In the logistic regression model in [Table 5](#T0005){ref-type="table"}, when the risk factors that were significantly correlated in [Table 4](#T0004){ref-type="table"} were put into the model, creatinine levels were the main predictor of CKD. Table 5Logistic regression analysis of risk factors for CKDVariablesExp. B95% CI/Odds Ratio*p*-value**Weight (kg)**1.0830.982--1.1940.109**BMI (kg/m^2^)**0.9450.712--1.2540.693**PCV (%)**1.0330.936--1.1400.517**CD~4~ count (µmol/l)**1.0020.999--1.0050.116**Creatinine (µmol/l)**0.9330.903--0.9640.0001**ARV Type 1 (3TC/AZT/NVP)**1.5480.0001.000**ARV Type 2 (TDF/AZT/EFV)**1.4290.120--16.9980.778**ARV Type 3 (ABC/3TC/EFV)**0.1190.010--1.4260.093**ARV Type 4 (TDF/3TC/EFV)**0.1430.014--1.4180.097**ARV Type 5 (TDF/3TC/LPVr)**0.3060.034--2.7330.098[^6]

Discussion {#S0005}
==========

Our study showed that 15.3% of the HIV subjects had CKD, and the risk factors associated with the development of CKD were lower levels of CD~4~ count below 200 cells/µL, lower PCV, weight, BMI and eGFR. Also, higher levels of WHR and creatinine were associated with CKD. Factors directly correlated with CKD were weight; BMI and CD~4~ count levels, while the creatinine levels were inversely correlated. However, a logistic regression model showed only creatinine to be a predictor of CKD.

The prevalence of 15.3% in our study is lower than that obtained from some Nigerian studies with a range of 22--51%,[@CIT0006]--[@CIT0009] but has similarity with the studies in USA with a range of 2--15.5%.[@CIT0026]--[@CIT0028] The difference noted in the prevalence of CKD in our study and the former reports may be adduced to the differences in sample size and HAART combination, as our study had protease inhibitor-based combination while the former reports were mainly nucleoside and nucleotide reverse transcriptase inhibitors combination.

This study showed that lower CD~4~ count is a risk factor for CKD, and lower CD~4~ count has also been shown to be associated with advanced HIV disease[@CIT0002] This finding in our study is in contrast with another study[@CIT0008] but in keeping with other studies where lower CD~4~ count was a predictor of CKD.[@CIT0006],[@CIT0029]

Also, studies have shown low BMI and hemoglobin to be predictors of CKD,[@CIT0008],[@CIT0030] but our study showed these parameters to be associated with CKD as risk factors as they were not significant in the logistic regression model.

In this study, tenofovir-based combination ARV therapy was associated with CKD in HIV patients; TDF/3TC/EFV combination was also a major implication.

Research has shown that tenofovir has been demonstrated to contribute to severe renal impairment in HIV-infected patients.[@CIT0022] There appears to be a consistent slight drop (up to 10%) in eGFR with the use of TDF, across some studies,[@CIT0031]--[@CIT0033] and appears to be more marked during the first years of exposure. However a study suggested that this decrease was largely irreversible,^30^ but the difference was of doubtful clinical significance. Studies have been conducted on patients who have initiated TDF in the presence of renal dysfunction and have shown that while the majority of patients did not deteriorate during study follow-up, those with pre-existing stage 2 (eGFR between 60 mL/min/1.73 m^2^ and 89 mL/min/1.73 m^2^) and stage 3 (30--59 mL/min/1.73 m^2^) renal disease were associated with progression to renal failure on TDF,[@CIT0034],[@CIT0035] although one study actually demonstrated improvement on TDF in patients with severe (\<30 mL/min/1.73 m^2^) renal failure

High levels of serum creatinine were found to be predictive of CKD in HIV patients in our study which is in keeping with earlier studies.[@CIT0006],[@CIT0008] Surprisingly, creatinine-based estimated GFR which is a more reliable tool in assessing renal function was associated with CKD but not predictive.[@CIT0036]

Our study did not demonstrate any association between gender and CKD in HIV patients, in contrast with a study that found female sex to be associated with CKD and another study which is in keeping with our findings.[@CIT0008],[@CIT0037]

According to a report by Agbaji et al,^37^ older age was associated with and a predictor of CKD in HIV patients. However, our study did not show such relationship, despite almost the same mean age of the subjects in their study and ours.[@CIT0037]

This study did not report any association between SBP, DBP, and CKD. This is in agreement with an earlier mentioned study.[@CIT0008] In contrast, some other studies reported SBP and DBP to be predictors of CKD.[@CIT0006],[@CIT0038] The difference with the later reports may be due to difference in study design.

Conclusion {#S0006}
==========

In conclusion therefore, the prevalence of CKD reported among HIV subjects in this study was 15.3% and the risk factors associated with CKD in HIV subjects on HAART were lower levels of CD4 count below 200 cells/µL, lower PCV, weight, BMI, and eGFR. Also, higher creatinine was associated and predictive of CKD in HIV subjects.

Limitations of the study {#S0007}
========================

It was a cross-sectional study carried out in one center which may not give a true prevalence of CKD in HIV patients in the South-South region of Nigeria, a multicenter study wwould be very helpful.

Also, other investigations that would have contributed to the risk factors and predictors of CKD were not measured; these include renal biopsy, HIV viral load, Hepatitis B and C, and lipid profile.

The authors acknowledge the University of Calabar Teaching Hospital HIV special clinic staff for their unreserved support during the study.
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[^1]: **Abbreviations:** ARV, antiretroviral; ABC, abacavir; AZT, zidovudine; EFV, efavirenz; 3TC, lamivudine; NVP, nevirapine; TDF, tenofovir; LPVr, lopinavir-retonavir.

[^2]: **Note:** \*Fisher's exact test.

    **Abbreviations:** ARV, antiretroviral; ABC, abacavir; AZT, zidovudine; EFV, efavirenz; 3TC, lamivudine; NVP, nevirapine; TDF, tenofovir; LPVr, lopinavir-retonavir.

[^3]: **Abbreviations:** HIV, human immunodeficiency virus; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; WHR, waist hip ratio; PCV, packed cell volume; eGFR, estimated glomerular filtration rate; ARV, antiretroviral.

[^4]: **Note:**\*Shows the level of correlation, where \* indicates weakly correlated while \*\* and above indicates strongly correlated.****

[^5]: **Abbreviations:** HIV, human immunodeficiency virus; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; WHR, waist hip ratio; PCV, packed cell volume; eGFR, estimated glomerular filtration rate; ARV, antiretroviral.

[^6]: **Abbreviations:**BMI, body mass index; WHR, waist hip ratio; PCV, packed cell volume; eGFR, estimated glomerular filtration rate; EFV, efavirenz; 3TC, lamivudine; AZT, zidovudine; NVP, nevirapine; ARV, antiretroviral; LPVr, lopinavir-retonavir.
